Skip to main content
Top
Published in: Current Treatment Options in Oncology 3/2014

01-09-2014 | Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Optimal Treatment Strategies for Anal Cancer

Authors: Shahab Ahmed, MD, Cathy Eng, MD, FACP

Published in: Current Treatment Options in Oncology | Issue 3/2014

Login to get access

Opinion statement

Squamous cell carcinoma (SCCA) of the anal canal is an underrecognized malignancy that is growing in annual incidence. Over the years, combined chemoradiation has been the mainstay of treatment for locally advanced SCCA of the anal canal. Currently, the human papilloma virus (HPV) vaccine is recommended to prevent the development of HPV and its associated precancerous lesion(s). Patients diagnosed with the human immunodeficiency virus (HIV+) are prone to develop anal cancer due to their high risk of contracting HPV infection. We will focus on the development and management of SCCA of the anal canal (both localized and metastatic), including special details on HIV-positive patients. Highlights will include the role of targeted therapy based on available literature. Our objective is to aid practicing physicians in formulating a treatment plan for both locally advanced and metastatic patients.
Literature
1.
2.
go back to reference ACS, A.C.S. Cancer Facts & Figures 2014. 2014. ACS, A.C.S. Cancer Facts & Figures 2014. 2014.
4.
go back to reference Ryan DP, Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000;12(4):345–52.PubMedCrossRef Ryan DP, Mayer RJ. Anal carcinoma: histology, staging, epidemiology, treatment. Curr Opin Oncol. 2000;12(4):345–52.PubMedCrossRef
6.
go back to reference Edge ST, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Anus. In: AJCC Cancer Staging Manual. 7th edition. Springer. 2010;165–73. Edge ST, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Anus. In: AJCC Cancer Staging Manual. 7th edition. Springer. 2010;165–73.
7.
go back to reference Daling JR et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270–80.PubMedCrossRef Daling JR et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004;101(2):270–80.PubMedCrossRef
8.
go back to reference Frisch M et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350–8.PubMedCrossRef Frisch M et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997;337(19):1350–8.PubMedCrossRef
9.
go back to reference Jimenez W et al. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol. 2009;114(3):395–8.PubMedCrossRef Jimenez W et al. Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol. 2009;114(3):395–8.PubMedCrossRef
10.
go back to reference Sunesen KG et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer. 2010;127(3):675–84.PubMedCrossRef Sunesen KG et al. Immunosuppressive disorders and risk of anal squamous cell carcinoma: a nationwide cohort study in Denmark, 1978-2005. Int J Cancer. 2010;127(3):675–84.PubMedCrossRef
12.
go back to reference National Cancer Institute, N., Anal Cancer Treatment. 2014. National Cancer Institute, N., Anal Cancer Treatment. 2014.
13.•
go back to reference Chin YJ, Hong ST, Wo JY. Anal cancer: current and future treatment strategies. Gastrointest Cancer: Targets and Ther. 2013;3:19–27. This article is informative of current anal cancer treatment options. Chin YJ, Hong ST, Wo JY. Anal cancer: current and future treatment strategies. Gastrointest Cancer: Targets and Ther. 2013;3:19–27. This article is informative of current anal cancer treatment options.
15.
go back to reference Klotz Jr RG, Pamukcoglu T, Souilliard DH. Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer. 1967;20(10):1727–45.PubMedCrossRef Klotz Jr RG, Pamukcoglu T, Souilliard DH. Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer. 1967;20(10):1727–45.PubMedCrossRef
17.
go back to reference Nigro ND, Vaitkevicius VK, Considine Jr B. Combined therapy for cancer of the anal canal: a preliminary report, 1974. Dis Colon Rectum. 1993;36(7):709–11.PubMedCrossRef Nigro ND, Vaitkevicius VK, Considine Jr B. Combined therapy for cancer of the anal canal: a preliminary report, 1974. Dis Colon Rectum. 1993;36(7):709–11.PubMedCrossRef
18.
go back to reference Sato H, Koh PK, Bartolo DC. Management of anal canal cancer. Dis Colon Rectum. 2005;48(6):1301–15.PubMedCrossRef Sato H, Koh PK, Bartolo DC. Management of anal canal cancer. Dis Colon Rectum. 2005;48(6):1301–15.PubMedCrossRef
19.
go back to reference Cummings BJ et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–25.PubMedCrossRef Cummings BJ et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991;21(5):1115–25.PubMedCrossRef
20.
go back to reference Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum. 1992;35(5):422–9.PubMedCrossRef Papillon J, Chassard JL. Respective roles of radiotherapy and surgery in the management of epidermoid carcinoma of the anal margin. Series of 57 patients. Dis Colon Rectum. 1992;35(5):422–9.PubMedCrossRef
21.
go back to reference Flam MS et al. Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases. Cancer. 1983;51(8):1378–87.PubMedCrossRef Flam MS et al. Definitive nonsurgical therapy of epithelial malignancies of the anal canal. A report of 12 cases. Cancer. 1983;51(8):1378–87.PubMedCrossRef
22.
go back to reference Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348(9034):1049–54. doi:10.1016/S0140-6736(96)03409-5. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet. 1996;348(9034):1049–54. doi:10.​1016/​S0140-6736(96)03409-5.
23.
go back to reference Bartelink H et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040–9.PubMed Bartelink H et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040–9.PubMed
24.
go back to reference Northover J et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123–8.PubMedCentralPubMedCrossRef Northover J et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010;102(7):1123–8.PubMedCentralPubMedCrossRef
25.
go back to reference Peiffert D et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941–8.PubMedCrossRef Peiffert D et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30(16):1941–8.PubMedCrossRef
26.
go back to reference Ajani JA et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–21.PubMedCrossRef Ajani JA et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–21.PubMedCrossRef
27.••
go back to reference Gunderson LL et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–51. This contains the recent updates on RTOG 98-11 trial.PubMedCentralPubMedCrossRef Gunderson LL et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30(35):4344–51. This contains the recent updates on RTOG 98-11 trial.PubMedCentralPubMedCrossRef
28.•
go back to reference Glynne Jones R, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. 2012 ASCO Annual Meeting Abstract.J Clin Oncol. 2012, 30 (suppl 15; abstr 4004). Available from: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4004. This study assesses the complete response rate at different time points following combined modality therapy. Glynne Jones R, et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: results of ACT II. 2012 ASCO Annual Meeting Abstract.J Clin Oncol. 2012, 30 (suppl 15; abstr 4004). Available from: http://​meeting.​ascopubs.​org/​cgi/​content/​abstract/​30/​15_​suppl/​4004. This study assesses the complete response rate at different time points following combined modality therapy.
29.••
go back to reference James RD et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14(6):516–24. This is a pivotal study in the management of squamous cell carcinoma of the anal canal.PubMedCrossRef James RD et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14(6):516–24. This is a pivotal study in the management of squamous cell carcinoma of the anal canal.PubMedCrossRef
30.•
go back to reference Eng C et al. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013;119(21):3769–75. This review supports the use of cisplatin in combination therapy for locally advanced squamous cell carcinoman of the anal canal.PubMedCrossRef Eng C et al. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. Cancer. 2013;119(21):3769–75. This review supports the use of cisplatin in combination therapy for locally advanced squamous cell carcinoman of the anal canal.PubMedCrossRef
31.
go back to reference Kam MK et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–9.PubMedCrossRef Kam MK et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–9.PubMedCrossRef
32.
go back to reference Ashman JB et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(3):765–71.PubMedCrossRef Ashman JB et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63(3):765–71.PubMedCrossRef
33.
go back to reference Kachnic LA et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.PubMedCentralPubMedCrossRef Kachnic LA et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013;86(1):27–33.PubMedCentralPubMedCrossRef
34.
go back to reference Milano MT et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–61.PubMedCrossRef Milano MT et al. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005;63(2):354–61.PubMedCrossRef
35.
go back to reference Salama JK et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25(29):4581–6.PubMedCrossRef Salama JK et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007;25(29):4581–6.PubMedCrossRef
36.
go back to reference Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Cancer Netw. 2010;8(1):123–9. Pepek JM, Willett CG, Czito BG. Radiation therapy advances for treatment of anal cancer. J Natl Compr Cancer Netw. 2010;8(1):123–9.
37.
go back to reference Bazan JG et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117(15):3342–51.PubMedCrossRef Bazan JG et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011;117(15):3342–51.PubMedCrossRef
38.
go back to reference Kachnic LA et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):153–8.PubMedCrossRef Kachnic LA et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012;82(1):153–8.PubMedCrossRef
39.•
go back to reference DeFoe SG et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma–clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol). 2012;24(6):424–31.CrossRef DeFoe SG et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma–clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol). 2012;24(6):424–31.CrossRef
40.•
go back to reference Mitchell MP, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2013. This article describes the role of IMRT and its toxicity in the management of localized squamous cell carcinoma of the anal canal. Mitchell MP, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2013. This article describes the role of IMRT and its toxicity in the management of localized squamous cell carcinoma of the anal canal.
41.
go back to reference Chuong MD et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6(2):39–45.PubMedCentralPubMed Chuong MD et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013;6(2):39–45.PubMedCentralPubMed
42.
go back to reference Ghouti L et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum. 2005;48(1):16–22.PubMedCrossRef Ghouti L et al. Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum. 2005;48(1):16–22.PubMedCrossRef
43.
go back to reference Nilsson PJ et al. Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep. 2006;16(3):443–9.PubMed Nilsson PJ et al. Prognostic significance of Cyclin A in epidermoid anal cancer. Oncol Rep. 2006;16(3):443–9.PubMed
44.
go back to reference Chessin DB et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol. 2005;12(2):104–10.PubMedCrossRef Chessin DB et al. Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol. 2005;12(2):104–10.PubMedCrossRef
45.
go back to reference Butler CE, Gundeslioglu AO, Rodriguez-Bigas MA. Outcomes of immediate vertical rectus abdominis myocutaneous flap reconstruction for irradiated abdominoperineal resection defects. J Am Coll Surg. 2008;206(4):694–703.PubMedCrossRef Butler CE, Gundeslioglu AO, Rodriguez-Bigas MA. Outcomes of immediate vertical rectus abdominis myocutaneous flap reconstruction for irradiated abdominoperineal resection defects. J Am Coll Surg. 2008;206(4):694–703.PubMedCrossRef
46.
go back to reference Sunesen KG et al. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol. 2009;16(1):68–77.PubMedCrossRef Sunesen KG et al. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol. 2009;16(1):68–77.PubMedCrossRef
47.
go back to reference Lefevre JH et al. Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg. 2009;250(5):707–11.PubMedCrossRef Lefevre JH et al. Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg. 2009;250(5):707–11.PubMedCrossRef
48.
go back to reference Nunez JE et al. Abdominoperineal resection in anal cancer: reconstruction of the perineum with a myocutaneous flap from the anterior rectus abdominis muscle. Cir Esp. 2011;89(1):31–6.PubMedCrossRef Nunez JE et al. Abdominoperineal resection in anal cancer: reconstruction of the perineum with a myocutaneous flap from the anterior rectus abdominis muscle. Cir Esp. 2011;89(1):31–6.PubMedCrossRef
49.••
go back to reference Dewdney A, Rao S. Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN Oncol. 2012;2012:756591. This informative reference describes the development on metastatic squamous cell cracinoma of the anal canal.PubMedCentralPubMed Dewdney A, Rao S. Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN Oncol. 2012;2012:756591. This informative reference describes the development on metastatic squamous cell cracinoma of the anal canal.PubMedCentralPubMed
50.
go back to reference Wilking N et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol. 1985;15(3):300–2.PubMedCrossRef Wilking N et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol. 1985;15(3):300–2.PubMedCrossRef
51.
go back to reference Hainsworth JD et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer. 2001;92(3):642–9.PubMedCrossRef Hainsworth JD et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer. 2001;92(3):642–9.PubMedCrossRef
52.
go back to reference Jhawer M et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Investig New Drugs. 2006;24(5):447–54.CrossRef Jhawer M et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282. Investig New Drugs. 2006;24(5):447–54.CrossRef
53.
go back to reference Faivre C et al. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999;86(10):861–5.PubMed Faivre C et al. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999;86(10):861–5.PubMed
54.
go back to reference Ajani JA et al. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989;87(2):221–4.PubMedCrossRef Ajani JA et al. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989;87(2):221–4.PubMedCrossRef
55.
go back to reference Khater R et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep. 1986;70(11):1345–6.PubMed Khater R et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep. 1986;70(11):1345–6.PubMed
56.
go back to reference Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol. 1993;16(6):536–40.PubMedCrossRef Jaiyesimi IA, Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol. 1993;16(6):536–40.PubMedCrossRef
57.
go back to reference Eng C, Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008;9(4–6):400–7.PubMedCrossRef Eng C, Pathak P. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008;9(4–6):400–7.PubMedCrossRef
58.•
go back to reference Eng C, et al. Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal. 2012 Annual ASCO Meeting. J Clin Oncol 30, 2012 (suppl; abstr 4060). Available from: http://meetinglibrary.asco.org/content/100733-114. This refers to currently available options for treating metastatic squamous cell carcinoma of anal canal. Eng C, et al. Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal. 2012 Annual ASCO Meeting. J Clin Oncol 30, 2012 (suppl; abstr 4060). Available from: http://​meetinglibrary.​asco.​org/​content/​100733-114. This refers to currently available options for treating metastatic squamous cell carcinoma of anal canal.
59.
go back to reference Rogers JE, et al. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2014. Rogers JE, et al. Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2014.
60.
go back to reference De Dosso S et al. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori. 2010;96(4):627–8.PubMed De Dosso S et al. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori. 2010;96(4):627–8.PubMed
61.
go back to reference Lukan N et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77(5):293–9.PubMedCrossRef Lukan N et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77(5):293–9.PubMedCrossRef
65.••
go back to reference Garg M, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. 2012 ASCO Annual Meeting Abstracts. J Clin Oncol. 2012, 30 (suppl 15; abstr 4030). Available from: http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/4030. This article is based on anti-EGFR roles on HIV negative and HIV patients with squamous cell carcinoma of the anal canal. Garg M, et al. Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): safety and preliminary efficacy results. 2012 ASCO Annual Meeting Abstracts. J Clin Oncol. 2012, 30 (suppl 15; abstr 4030). Available from: http://​meeting.​ascopubs.​org/​cgi/​content/​abstract/​30/​15_​suppl/​4030. This article is based on anti-EGFR roles on HIV negative and HIV patients with squamous cell carcinoma of the anal canal.
66.
go back to reference Deutsch E, et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. 2011 ASCO Annual Meeting. General Poster Session, Gastrointestinal (Noncolorectal) Cancer. J Clin Oncol. 2011, 29 (suppl; abstr 4098). Available from: http://meetinglibrary.asco.org/content/81933-102. Deutsch E, et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: Interim results of the French multicenter phase II trial ACCORD16. 2011 ASCO Annual Meeting. General Poster Session, Gastrointestinal (Noncolorectal) Cancer. J Clin Oncol. 2011, 29 (suppl; abstr 4098). Available from: http://​meetinglibrary.​asco.​org/​content/​81933-102.
67.
go back to reference Patel P et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728–36.PubMedCrossRef Patel P et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148(10):728–36.PubMedCrossRef
68.
go back to reference Kim JH et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44(10):1496–502.PubMedCrossRef Kim JH et al. HIV-positive patients with anal carcinoma have poorer treatment tolerance and outcome than HIV-negative patients. Dis Colon Rectum. 2001;44(10):1496–502.PubMedCrossRef
69.
go back to reference Oehler-Janne C et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26(15):2550–7.PubMedCrossRef Oehler-Janne C et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008;26(15):2550–7.PubMedCrossRef
70.•
go back to reference Rubinstein P, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for invasive anal carcinoma in HIV-positive patients receiving highly active anti-retroviral therapy versus non-HIV patients. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e14590). Available from: http://meetinglibrary.asco.org/content/101205-114. This study compares the outcomes of HIV negative patients with anal cancer who receive chemoradiation versus HIV positive patients with anal cancer who receive chemoradiation and HAART. Rubinstein P, et al. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin-C for invasive anal carcinoma in HIV-positive patients receiving highly active anti-retroviral therapy versus non-HIV patients. 2012 ASCO Annual Meeting. J Clin Oncol 30, 2012 (suppl; abstr e14590). Available from: http://​meetinglibrary.​asco.​org/​content/​101205-114. This study compares the outcomes of HIV negative patients with anal cancer who receive chemoradiation versus HIV positive patients with anal cancer who receive chemoradiation and HAART.
71.
go back to reference Peddada AV et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1997;37(5):1101–5.PubMedCrossRef Peddada AV et al. Chemotherapy and low-dose radiotherapy in the treatment of HIV-infected patients with carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 1997;37(5):1101–5.PubMedCrossRef
72.
go back to reference Hoffman R et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44(1):127–31.PubMedCrossRef Hoffman R et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999;44(1):127–31.PubMedCrossRef
73.
go back to reference Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2006;66(1):206–11.PubMedCrossRef Edelman S, Johnstone PA. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2006;66(1):206–11.PubMedCrossRef
74.
go back to reference Stadler RF et al. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2004;47(8):1305–9.PubMedCrossRef Stadler RF et al. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2004;47(8):1305–9.PubMedCrossRef
75.•
go back to reference National Comprehensive Cancer Network, N. Anal Carcinoma, NCCN guidelines. 2014 (Version 2.2013). This refers to the current guidelines for the management of anal cancer in the United States. National Comprehensive Cancer Network, N. Anal Carcinoma, NCCN guidelines. 2014 (Version 2.2013). This refers to the current guidelines for the management of anal cancer in the United States.
Metadata
Title
Optimal Treatment Strategies for Anal Cancer
Authors
Shahab Ahmed, MD
Cathy Eng, MD, FACP
Publication date
01-09-2014
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 3/2014
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-014-0298-0

Other articles of this Issue 3/2014

Current Treatment Options in Oncology 3/2014 Go to the issue

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Liver-Directed Treatments for Metastatic Colorectal Cancer

Lower Gastrointestinal Cancers (AB Benson, Section Editor)

Chinese Herbal Medicines in the Treatment of IBD and Colorectal Cancer: A Review

Sarcoma (SH Okuno, Section Editor)

Surgical Treatment of Sarcomas of the Spine

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine